Webinar #7: Genetic Discoveries and Pathologic Variations in Ovarian Cancer

All times listed are Central Daylight Time (CDT).

Moderators/Distillants: Charles N. Landen, MD, and Barbara S. Norquist, MD

  • Histopathological characterization of the tubal fimbria reveals a subgroup of BRCA1 mutation carriers with tumor-promoting gene-set enrichment – Y. Raz
  • Metabolomic and transcriptomic response to neoadjuvant chemotherapy in HGSOC – A. M. Davis
  • Compositional and architectural characterization of high-grade serous ovarian carcinomas using single cell technologies and multiplex microscopy – S. H. Kim
  • BRCA tumor-testing in a tertiary referral center: Are we missing something or not? – C. Marchetti
  • Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma – J. J. Wallbillich
  • Inherited mutations in fallopian tube, ovarian, and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years – A. S. Weiss

Abstract PDF

 Registration Link For OnDemand Webinar (SGO ConnectEd)

Learning Objectives

  1. Identify two groups of postmenopausal BRCA1 mutation carriers that differ by histopathological criteria and relate the phenotype to tumor-promoting properties
  2. Identify the utility of transcriptomic analysis of primary patient samples to better characterize tumor differences.
  3. Identify the impact of single cell technologies in ovarian cancer
  4. Demonstrate that tumor-tissue testing represents a reliable, feasible and cost-saving screening-procedure for BRCA mutational status assessment.
  5. Illustrate the complexity of BRCA1 mediated platinum response in ovrian cancer
  6. Describe how homologous recombination gene mutation frequencies compare between USCs and HGSOCs
  7. Identify pertinent deleterious germline mutations present in fallopian tube carcinomas, as they compare to those seen in ovarian and primary peritoneal carcinomas and demonstrate how this had changed over time with the adoption of serial fallopian tube sectioning.

JOINT ACCREDITATION
In support of improving patient care, the Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

AMA Credit Designation Statement – Physicians
The Society of Gynecology Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.

ANCC Credit Designation Statement – Nurses
This activity has been approved for a maximum of 1.0 nursing contact hours.

ACPE Credit Designation Statement – Pharmacists
Each activity has been approved for a maximum of 1.0 contact hours of pharmacy continuing education credit. UAN number JA00007238-0000-20-011-L01-P.

PAs may claim a maximum of 1.0 AMA PRA Category 1 Credits™ for completing this live activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state or medical society.

Top